Chronic rhinosinusitis with nasal polyps (CRSwNP) is increasingly understood as a type 2 inflammatory disease. Which biological agent targeting the IL-4/IL-13 pathway has received regulatory approval for CRSwNP management?

• A Mepolizumab (anti-IL-5)
• B Dupilumab (anti-IL-4Rα) ✓
• C Omalizumab (anti-IgE)
• D Benralizumab (anti-IL-5Rα)

Explanation

Dupilumab (a monoclonal antibody targeting the IL-4 receptor alpha subunit, blocking both IL-4 and IL-13 signaling) is specifically approved for CRSwNP as an add-on therapy when standard treatment (intranasal corticosteroids and surgery) is insufficient. Both SINUS-24 and SINUS-52 trials demonstrated significant polyp reduction and symptom improvement. Omalizumab is also approved for CRSwNP. Mepolizumab and benralizumab target IL-5/eosinophil pathways and have evidence in CRSwNP but dupilumab targets the IL-4/IL-13 pathway specifically as asked.

Reference: Dhingra Diseases of Ear, Nose and Throat, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.